Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Medical Genetics

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Clinical and molecular characterization of a cohort of patients with novel nucleotide alterations of the Dystrophin gene detected by direct sequencing

  • Francesca Magri1,
  • Roberto Del Bo1,
  • Maria G D'Angelo2,
  • Alessandra Govoni1,
  • Serena Ghezzi1,
  • Sandra Gandossini2,
  • Monica Sciacco1,
  • Patrizia Ciscato1,
  • Andreina Bordoni1,
  • Silvana Tedeschi3,
  • Francesco Fortunato1,
  • Valeria Lucchini1,
  • Matteo Cereda2,
  • Stefania Corti1,
  • Maurizio Moggio1,
  • Nereo Bresolin1, 2 and
  • Giacomo P Comi1Email author
BMC Medical Genetics201112:37

https://doi.org/10.1186/1471-2350-12-37

Received: 2 November 2010

Accepted: 11 March 2011

Published: 11 March 2011

Abstract

Background

Duchenne and Becker Muscular dystrophies (DMD/BMD) are allelic disorders caused by mutations in the dystrophin gene, which encodes a sarcolemmal protein responsible for muscle integrity. Deletions and duplications account for approximately 75% of mutations in DMD and 85% in BMD. The implementation of techniques allowing complete gene sequencing has focused attention on small point mutations and other mechanisms underlying complex rearrangements.

Methods

We selected 47 patients (41 families; 35 DMD, 6 BMD) without deletions and duplications in DMD gene (excluded by multiplex ligation-dependent probe amplification and multiplex polymerase chain reaction analysis). This cohort was investigated by systematic direct sequence analysis to study sequence variation. We focused our attention on rare mutational events which were further studied through transcript analysis.

Results

We identified 40 different nucleotide alterations in DMD gene and their clinical correlates; altogether, 16 mutations were novel. DMD probands carried 9 microinsertions/microdeletions, 19 nonsense mutations, and 7 splice-site mutations. BMD patients carried 2 nonsense mutations, 2 splice-site mutations, 1 missense substitution, and 1 single base insertion. The most frequent stop codon was TGA (n = 10 patients), followed by TAG (n = 7) and TAA (n = 4). We also analyzed the molecular mechanisms of five rare mutational events. They are two frame-shifting mutations in the DMD gene 3'end in BMD and three novel splicing defects: IVS42: c.6118-3C>A, which causes a leaky splice-site; c.9560A>G, which determines a cryptic splice-site activation and c.9564-426 T>G, which creates pseudoexon retention within IVS65.

Conclusion

The analysis of our patients' sample, carrying point mutations or complex rearrangements in DMD gene, contributes to the knowledge on phenotypic correlations in dystrophinopatic patients and can provide a better understanding of pre-mRNA maturation defects and dystrophin functional domains. These data can have a prognostic relevance and can be useful in directing new therapeutic approaches, which rely on a precise definition of the genetic defects as well as their molecular consequences.

Background

Dystrophinopathies are a heterogeneous group of disorders caused by mutations in dystrophin (DMD) gene [1]. Duchenne Muscular Dystrophy (DMD; OMIM #310200) is the most severe form, with an incidence of 1 in 3,500 newborn males [2] and loss of independent ambulation before the age of 14 years [3]. Becker Muscular Dystrophy (BMD; OMIM #300376) is a milder and more heterogeneous allelic disorder with near-normal life expectancy [4].

Until recently, the genetic approach was limited to methods that were able to detect large deletions and duplications because the large size of the DMD gene made finer-scale mutation analysis prohibitively time consuming. In DMD patients, they account for 65% and 10% of mutations, respectively; in BMD, the mutation detection rate is 85% [5].

The recent implementation of diagnostic techniques with possibility to perform high-throughput direct sequencing of the DMD gene [6] has increased diagnostic sensitivity and focused attention on small point mutations and more complex gene rearrangements that otherwise would hardly be detected.

The analysis of both types of mutations, the study of their positions along the DMD gene and their effects on the transcript processing and protein levels helps to define the correlations with clinical presentation and to build a clear understanding of the molecular pathology of dystrophinopathies. The described single nucleotide substitutions and small nucleotide changes along the coding sequence, together with other more complex DMD gene rearrangements, are listed on the Leiden website http://www.dmd.nl/ and described in several works [712]. Knowledge about these small nucleotide changes can provide a better understanding of dystrophin functional domains, as well as the mechanisms underlying transcriptional and post-transcriptional events.

The overall number of described pre-RNA maturation defects and deep intronic mutations in the DMD gene is still relatively small, and their effects on mRNA processing and protein expression are often unknown [10, 1317]. The clinical usefulness of drawing conclusions about the prognosis of a given mutation based on a single or few reports is questionable.

Furthermore, the development of several new therapeutic approaches for DMD strongly relies on a precise definition of the genetic defects as well as their molecular consequences. Indeed, fundamental areas of therapeutic research on DMD/BMD are currently based on the usage of molecules that promote the read-through of pathological stop codons created by point mutations [18, 19]. A similar need for deeper understanding applies to the entire field of exon-skipping technologies based on our current knowledge of the process, which naturally regulates dystrophin mRNA maturation [20]. From this point of view, the analysis of naturally occurring aberrant splicing events might be instructive regarding the complex transcriptional mechanisms of the gigantic DMD gene.

Methods

Patient selection

A sample of 41 DMD and 6 BMD patients was shown to be negative for both deletions and duplications in the entire coding region of the DMD gene, as well as the adjacent splice site and muscle promoter regions, by multiplex ligation-dependent probe amplification (MLPA) and multiplex polymerase chain reaction (PCR) analysis.

Written informed consent was obtained (and preserved in original) from all subjects or their caregivers at the time of primary diagnostic procedures, with explicit consent to future uses for research purpose, according to the Declaration of Helsinki. This protocol was approved by the Institutional Review Board of the Fondazione I.R.C.C.S. Ca' Granda Ospedale Maggiore Policlinico - University of Milan.

The "Telethon Bank of DNA, Nerve and Muscle Tissues" (no. GTF02008), located in the Department of Neurological Sciences, Fondazione I.R.C.C.S. Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, was the source of the DNA samples used in this study.

Thirty-five probands showed a DMD clinical phenotype and the absence of dystrophin protein in muscle immunohistochemistry (IHC) and Western blot (WB) analysis with multiple anti-dystrophin antibodies, while six had a milder muscle involvement and variable muscle dystrophin expression consistent with a diagnosis of BMD.

In this cohort, we undertook a systematic study of sequence variation, by direct sequence analysis. The patients were regularly followed, with a complete clinical evaluation comprising cardiac, respiratory, and cognitive assessments.

Muscle tissue analysis

Muscle biopsy was taken from brachial biceps or quadriceps muscle after written informed consent as previously reported. According to standard techniques, the muscle sections were analyzed by morphological study and IHC analysis. Dystrophin IHC was performed [21] using monoclonal antibodies against mid-rod domain, NH2, and COOH epitopes (Novocastra, Newcastle upon Tyne, UK), and was completed using α-SG, β-SG, γ-SG, δ-SG, dysferlin (Novocastra), and caveolin-3 (Transduction Laboratories, Lexington, KY) monoclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) as described [2224]. Dystrophin defects revealed by IHC were confirmed by WB analysis using the same monoclonal antibodies.

Molecular analysis

DNA was extracted from peripheral blood samples according to standard procedures (Flexi Gene DNA Handbook, Quiagen). All patients were screened for deletions and duplications with multiplex PCR and MLPA as previously described [25].

Sequence analysis

All 79 exons and the exon-intron boundaries of the DMD gene were studied through PCR amplification and direct sequencing (ABI Prism 3100 Genetic Analyzer, Applied Biosystem, Foster City, USA) using published primer sets [26]. Mutations were named according to the Leiden Muscular Dystrophy database http://www.dmd.nl/ using the nomenclature system published in 2000 on Human Mutation [27] (reference sequence GenBank file NM_004006.1)

Transcript analysis

Patients with mutations leading to abnormal mRNA splicing were further investigated through transcript analysis. In these patients, mRNA was isolated from muscle tissue with Eurozol (EMR055100, EuroClone). The cDNA was produced through reverse transcription polymerase chain reaction (RT-PCR) (Ready-To-Go RT-PCR kit, Amersham Pharmacia) and analyzed by amplification and sequencing. Transcript analysis was performed using primers previously published by Roberts et al. [26]. New primers were designed in some specific cases. All primer sequences are available on request.

Bioinformatics analysis

To estimate the effect of the T/G mutation in intron 65 of the DMD gene, we used the splice site models introduced by Yeo and Burge [28] and the software available at: http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq_acc.html. The sequences CTGGTAATT and CTGGTAAGT, which correspond respectively to the wild-type and mutated 5' splice site of the included exon were scored. We obtained maxENT scores, which represents the probability that a sequence is a functional splice site. Therefore, as suggested by Enl et al. [29], given two sequences of differing scores, the higher-scoring sequence has a higher likelihood of being used as 5' splice site.

Results

We selected 47 patients (41 probands) carrying nucleotide alterations in the DMD gene; 41 patients were affected with DMD and 6 with BMD.

The distribution of the mutations in DMD families was as follows: 9 micro-insertions or microdeletions, 19 nonsense substitutions, 7 splice-site mutations.

Among BMD subjects, 2 carried nonsense mutations, 2 showed splice-site mutations, 1 had a missense substitution, and 1 patient presented with the insertion of a single nucleotide (Figure 1). The most frequent stop codon was TGA (n = 10 patients) followed by TAG (n = 7 patients) and TAA (n = 4 patients). Altogether, 16 mutations were novel.
Figure 1

Distribution of mutations along the DMD gene. Each box corresponds to an exon, with different colours indicating the four different functional portions of the gene: actin-binding domain (exons 1-8, yellow); rod domain (exons 9-62, blue); cysteine-rich domain (exons 63-69, green); C-terminal domain (exons 70-79, red). Mutations identified in the BMD population are listed in the upper part of the figure, while mutations found in the DMD population are listed in the lower section. Intronic mutations are listed in blue.

The mean age at diagnosis of the entire DMD group was 2.8 ± 1.3 years (range 1-6 years) while BMD patients came to medical attention at approximately 14 ± 20 years (range 3-46 years). Fifty-six percent of DMD patients were wheelchair bound; they lost independent ambulation at a mean age of 10.1 years. The clinical and molecular characteristics of this population are summarized in Table 1.
Table 1

Clinical and molecular characteristics of patients carrying point mutations in DMD gene

Pt N.

BMD vs DMD

Mutation

Effect of mutation

Exon/intron

Stop codon

Reference

Age of onset/diagnosis(ys)

Symptoms at onset

CK levels (UI/L)

Age CK

Loss of ambulation (age)

I

BMD

Insertion

c.10453insC

p.Leu3485ProfsX6

74

 

[33]

7

HyperCKemia

12922

7

No (9)

II

BMD

Nonsense

c.9G>A

p.Trp3X

1

TGA

[10]

3

HyperCKemia

3300

3

No (7)

III

BMD

Nonsense

c.10783C>T

p.Gln3595X

75

TAG

[35]

nd

nd

nd

nd

Yes (22)

IV

BMD

Missense

c.352T>A

p.Trp118Arg

5

 

Novel

45

Motor impairment

nd

nd

No (49)

V

BMD

Splicing

c.1705-8T>C

cDNA analysis NOT done

IVS14

 

Novel

2

hyperCKemia

1604

2

No (5)

VI

BMD

Splicing

c.6118-3C>A

cDNA analysis NOT done

IVS42

 

Novel

49

Motor impairment

1400

46

No (68)

VII

DMD

Insertion

c.151insC

p.Leu51ProfsX37

3

 

Novel

nd

nd

nd

nd

nd

VIII

DMD

Duplication

c.3009dupTG

p.Lys1004X

23

 

Novel

nd

nd

nd

nd

nd

IX

DMD

Duplication

c.5773_5794dup

p.Gln1932ArgfsX6

41

 

Novel

1

HyperCKemia

2956

17

Yes (12)

X.1

DMD

Insertion

c.7548insGGCAACA

p.Met2517GlyfsX49

52

 

Novel

nd

nd

nd

nd

nd

X.2

DMD

Insertion

c.7548insGGCAACA

p.Met2517GlyfsX49

52

 

Novel

nd

nd

nd

nd

nd

XI

DMD

Deletion

c.6353delA

p.Gln2118ArgfsX3

44

 

Novel

2

HyperCKemia

16159

2

No (13)

XII.1

DMD

Deletion

c.6986delA

p.Lys2329SerfsX8

48

 

[37]

1

HyperCKemia

11493

1

No (1)

XII.2

DMD

Deletion

c.6986delA

p.Lys2329SerfsX8

48

 

[37]

3

Motor impairment

32359

3

No (4)

XIII

DMD

Deletion

c.9204_9207delCAAA

p.Asn3068LysfsX19

62

 

Leiden database

4

HyperCKemia

7671

6

Yes (8)

XIV

DMD

Deletion

c.10386delT

p.Asn3462LysfsX3

73

 

Novel

nd

nd

4760

11

Yes (12)

XV.1

DMD

Del/ins

c.1603delGTAinsCT

p.Val535LeufsX47

14

 

Novel

nd

nd

12000

9

Yes (13)

XV.2

DMD

Del/ins

c.1603delGTAinsCT

p.Val535LeufsX47

14

 

Novel

nd

nd

2061

13

Yes (12)

XV.3

DMD

Del/ins

c.1603delGTAinsCT

p.Val535LeufsX47

14

 

Novel

nd

nd

5357

9

Yes (10)

XVI

DMD

Nonsense

c.568C>T

p.Gln190X

7

TAG

[10]

3

Motor impairment

12800

6

No (6)

XVII

DMD

Nonsense

c.2956C>T

p.Gln986X

23

TAA

[35]

3

Motor impairment

10430

3

Yes (11)

XVIII

DMD

Nonsense

c.3580C>T

p.Gln1194X

26

TAG

[10]

3

HyperCKemia

13580

3

No (7)

XIX

DMD

Nonsense

c.4117C>T

p.Gln1373X

30

TAG

Leiden database

2

HyperCKemia

7246

5

No (6)

XX

DMD

Nonsense

c.4996C>T

p.Arg1666X

35

TGA

38]

1

Delayed motor milestones

8000

1

No (7)

XXI

DMD

Nonsense

c.5209C>T

p.Arg1737X

37

TAA

Novel

2

HyperCKemia

nd

nd

No (2)

XXII

DMD

Nonsense

c.5530C>T

p.Arg1844X

39

TGA

[38]

3

Motor impairment

19000

5

No (6)

XXIII.1

DMD

Nonsense

c.5563C>T

p.Gln1855X

39

TAG

[35]

3

HyperCKemia

19452

4

No (7)

XXIII.2

DMD

Nonsense

c.5563C>T

p.Gln1855X

39

TAG

[35]

2

No symptoms

nd

 

No (5)

XXIV

DMD

Nonsense

c.6277A>T

p.Lys2093X

43

TAG

Novel

1

Delayed motor milestones

17000

1

No (5)

XXV.1

DMD

Nonsense

c.6943G>T

p.Glu2315X

48

TAA

[39]

3

Motor impairment

1918

12

Yes (8)

XXV.2

DMD

Nonsense

c.6943G>T

p.Glu2315X

48

TAA

[39]

3

Motor impairment

7583

9

No (8)

XXVI

DMD

Nonsense

c.8038C>T

p.Arg2680X

55

TGA

[40]

4

Delayed speech

3211

11

Yes (9)

XXVII

DMD

Nonsense

c.8608C>T

p.Arg2870X

58

TGA

Leiden database

1

Delayed motor milestones

12954

9

No (10)

XXVIII

DMD

Nonsense

c.8944C>T

p.Arg2982X

60

TGA

[38]

4

Delayed motor milestones

8617

7

No (8)

XXIX

DMD

Nonsense

c.9100C>T

p.Arg3034X

61

TGA

[10]

6

Delayed motor milestones

15000

1

No (8)

XXX

DMD

Nonsense

c.10108C>T

p.Arg3370X

70

TGA

[40]

4

Delayed motor milestones

8891

1

No (9)

XXXI

DMD

Nonsense

c.10108 C>T

p.Arg3370X

70

TGA

[40]

4

Delayed motor milestones

2312

10

Yes (10)

XXXII

DMD

Nonsense

c.10141C>T

p.Arg3381X

70

TGA

[40]

nd

nd

nd

nd

No (4)

XXXIII

DMD

Nonsense

c.10219G>T

p.Glu3407X

70

TAA

Novel

4

HyperCKemia

9200

4

No (11)

XXXIV

DMD

Nonsense

c.10651C>T

p.Gln3551X

75

TAG

Novel

1

Delayed motor milestones

13672

2

nd

XXXV

DMD

Splicing

c.9560A>G

p.Asp3187Gly

65

 

[39]

4

HyperCKemia

17634

5

No (6)

XXXVI

DMD

Splicing

c.358-2A>T

cDNA analysis NOT done

IVS5

 

[10]

4

nd

3904

10

Yes (8)

XXXVII

DMD

Splicing

c.2949+1G>T

cDNA analysis NOT done

IVS22

 

[12]

nd

Delayed motor milestones

11834

1

nd

XXXVIII

DMD

Splicing

c.6118-1G>A

cDNA analysis NOT done

IVS42

 

Leiden database

nd

nd

nd

 

nd

XXXIX

DMD

Splicing

c.8668+3A>T

cDNA analysis NOT done

IVS58

 

Novel

3

HyperCKemia

11815

3

Yes (10)

XL

DMD

Splicing

c.9563_9564ins53

p.Thr3188=fsX7

IVS65

 

Novel

4

HyperCKemia

16000

4

No (6)

XLI

DMD

Splicing

c.10086+1G>A

cDNA analysis NOT done

IVS69

 

[36]

1

Delayed motor milestones

7365

1

Yes (9)

In the majority of patients, phenotype (DMD versus BMD) was predicted by genotype, according to the reading frame rule. However, we observed exceptions to this rule in 2 of 34 DMD cases and 4 of 6 BMD cases. Patient II, carrying the nonsense mutation p.Trp3X has been previously described (patient VII, R007) [30]. Clinical and molecular data regarding the other five cases, relevant to the issue of the reading frame rule or presenting rare aberrant mRNA maturation, are described in detail.

Patient I: Creation of a stop codon at the 3' end of the DMD gene is associated with a mild BMD phenotype

A 7-year-old boy came to medical attention because of occasionally high creatine kinase (CK) levels (12,922 IU/L) during bladder infection. He was completely asymptomatic, showing only mild calf hypertrophy and Achilles tendon retraction, with no muscular weakness. He had neither cardiac nor respiratory impairment. Full Intelligence Quotient (IQ) level was normal.

A muscle biopsy performed on the brachial biceps at 7 years of age showed a mild dystrophic pattern with moderate connective tissue increase, fibre size variability, and 3-4 necrotic fibres. IHC revealed decreased reactivity with antibody against NH2 and Rod-domain and complete absence of signal with antibodies directed towards the COOH-terminal epitope. Molecular analysis demonstrated the presence of a single nucleotide insertion in exon 74 (c.10453insC). This insertion leads to a frame shift mutation with the creation of a premature stop codon (p.Leu3485ProfsX6) (Figure 2A) and does not fit with the mild clinical presentation of the patient.
Figure 2

Patient I: stop codon at the 3' end of DMD gene in mild BMD phenotype. Molecular and muscle biopsy features in patient I. The patient showed a mild BMD phenotype and carried a mutation that creates a stop codon at the 3' end of the DMD gene. In the upper part of the figure, the schematic representation of the DMD gene depicts the position of the mutation, which is located in exon 74. A. Sequence analysis of genomic DNA. Pt (Patient I): The electropherogram depicts the single base pair insertion c.10453insC (black arrow). Under the electropherogram, the predicted amino acid sequence demonstrates the effect of the mutation, which leads to the out-of-frame transcript p.Leu3485ProfsX6. Ctr: Control. B. Dystrophin Western blot analysis of a muscle biopsy sample from patient I revealed decreased immunoblot staining with antibody directed against the dystrophin mid-rod domain (DYS1), and absence of signal with antibodies directed towards the C-terminal epitope (DYS2). Ctr: Control muscle sample.

The protein data were further confirmed by dystrophin WB analysis on muscle homogenate, which showed the presence of a truncated protein lacking of the C-terminal domain (Figure 2B); although decreased in molecular weight and amount, this protein is still able to localize to the membrane as demonstrated by IHC.

Patient III: Nonsense mutation located at the 3' end of the DMD gene is associated with a severe BMD phenotype

This patient presented with a severe BMD phenotype. He started to complain muscular impairment with difficulties in running and climbing stairs at 9 years of age. Motor involvement displayed a fast, progressive course with loss of independent ambulation at 22 years of age. At 19 years of age, he also developed severe cardiac involvement with arrhythmia and hypocinesia. After 3 years, he presented with a reduction of ejection fraction (40%) and started cardiac therapy. He also presented with a restrictive respiratory pattern, but did not require non-invasive mechanical ventilation. At 27 years of age, this patient had stable clinical parameters.

Muscle tissue analysis revealed a severe dystrophic pattern and weak sarcolemmal signal with DYS rod-domain antibodies. After exclusion of deletions and duplications of the DMD gene, sequence analysis showed a single nucleotide substitution (c.10783C>T) (Figure 3) that is predicted to create a stop codon in exon 75 (p.Gln3595X). This "null" mutation was also compatible with partial dystrophin production, even if the quantity of protein, as evaluated by WB analysis, was lower than in the case of Patient I.
Figure 3

Patient III: Nonsense mutation at the 3' end of DMD gene in severe BMD phenotype. The mutation is localized in exon 75 (see schematic representation of the DMD gene).. Sequence analysis revealed the nucleotide substitution c.10783C>T (black arrow). This mutation leads to the creation of a stop codon (p.Gln3595X).

Patient VI: Leaky splice site mutation and double transcript in a BMD patient

The patient showed a BMD phenotype with late onset, at 49 years of age. He complained of pain, muscle wasting of the quadriceps, and lower limb girdle muscle weakness. Although the disease had a progressive course, the patient was still ambulant at 68 years of age, manifesting only mild difficulty in postural adjustments.

A muscle biopsy conducted at 50 years of age revealed mild myopathic changes with a slight lipid increase. A repeated biopsy performed at 58 years of age demonstrated a dystrophic pattern with fibre size variability, as well as several nuclear centralizations and fiber splittings. Connective tissue was normal in all samples. IHC analysis revealed mild sarcolemmal staining with the three antibodies. WB showed a mild intensity reduction with both DYS1 and DYS2 antibodies, and sarcoglycan immunostaining was also decreased. The screening of the DMD gene for deletions and duplications with multiple-PCR and MLPA and the analysis of the four sarcoglycan genes by direct sequencing showed no mutations.

DMD gene sequencing revealed a c.6118-3C>A nucleotide substitution in IVS42 (Figure 4A). This novel mutation is expected to determine the skipping of exon 42 with production of an out-of-frame transcript associated with severe DMD phenotype.
Figure 4

Patient VI: Leaky splice site mutation and double transcript in a BMD patient. The mutation is localized within intron 42 (see schematic representation of the DMD gene reproduced in the upper part of the figure). A. Genomic analysis of the 3' splice site of intron 42 in patient VI. The electropherogram depicts the nucleotide substitution c.6118-3C>A in IVS42 (red box). B. Agarose gel electrophoretic analysis of PCR products derived from the RT-PCR of DMD cDNA nucleotides 5959-6624 form patient VI's muscle-derived cDNA. Transcript analysis reveals the presence of two different RT-PCR products in the patient (Pt): the expected 665-bp full-length band, and a shorter 493-bp band; the RT-PCR product from a control subject demonstrates the presence of the wild-type 665-bp band. C. Sequence analysis of the RT-PCR products demonstrates that the 665-bp band corresponds to the full-length cDNA, while the 493-bp band corresponds to a product carrying the deletion of exon 43.

The mild clinical presentation of Patient VI was explained by transcript analysis.

In fact, study of the transcript revealed the presence of two different products (Figure 4B): a 665-bp band corresponding to full-length PCR products (Figure 4B, upper transcript) and a more intense band of lower molecular weight, corresponding to the exon 43-deleted product (Figure 4B, lower transcript). The data were therefore consistent with the hypothesis that a leaky out-of-frame splice defect led to the production of a decreased amount of normal full-length DYS cDNA and a decreased amount of normal dystrophin.

Patient XXXV: Coding region point mutation activates a cryptic exonic splice site

A 4-year-old boy presented with occasionally high CK levels (17,634 IU/L) confirmed at further analysis. At 6 years of age, he displayed moderate proximal muscle weakness in the upper and lower limbs with positive Gowers' manoeuvre, and was started on corticosteroid therapy. Patient XXXV also showed mild cognitive impairment with difficulties at elementary school. He had no cardiac or respiratory involvement.

Muscle biopsy obtained from brachial biceps demonstrated a dystrophic pattern. IHC analysis showed a complete absence of dystrophin. Multiplex-PCR and MLPA analysis revealed no deletions or duplications. Gene sequencing revealed a novel substitution (c.9560A>G) in one of the last nucleotides of exon 65 (Figure 5A). Although the mutation predictably causes a missense mutation that results in an amino acid change at position 3187 (p.Asp3187Gly), this hypothesis did not fit with the clinical presentation of the patient.
Figure 5

Patient XXXV: Coding region point mutation activates a cryptic exonic splice site. The mutation is localized in exon 65 (see schematic representation of the DMD gene). A. Sequence analysis. An electropherogram depicting the nucleotide substitution c.9560A>G, which would putatively result in an amino acid substitution (p.Asp3187Gly). B. Transcript analysis. The nucleotide substitution activates a cryptic splice site with skipping of the last 4 nucleotides of exon 65 (Pt: patient; Ctr: control), which changes the reading frame.

Through transcript analysis we ascertained that this nucleotide substitution determines the activation of a cryptic splice site, resulting in skipping of the last four nucleotides of exon 65 with consequent change of the reading frame and creation of an out-of-frame transcript (Figure 5B). Nucleotide substitutions located near intron-exon boundaries mimicking missense mutations can modify the splicing process, creating a new splice site even if they are not located in typical splice sites.

Patient XL: An intronic nucleotide substitution activates a cryptic splice site and leads to pseudoexon creation

This patient came to our attention as a 4-year-old boy presenting with occasionally high CK levels (7,000 IU/L). He was the first boy of healthy parents with a family history negative for muscle disorders. At first evaluation, he showed mild calf hypertrophy and frequent falling. During the following two years he developed mild proximal lower limb weakness with Gowers' sign and running difficulties. Patient XL never learned to run and was able to climb the stairs only with the aid of a handrail. He had no cardiac, respiratory, or cognitive impairments.

At 6 years of age, Patient XL underwent muscle biopsy on the brachial biceps. Muscle tissue analysis revealed a dystrophic pattern with moderate fibre size variability, rare nuclear centralization, and fibre splittings, as well as few instances of necrosis. Interstitial cellular infiltrates were absent. Connective tissue was increased. IHC analysis demonstrated the complete absence of dystrophin on muscle membrane with the antibodies directed against all three epitopes. A mild reduction with α-SG antibodies was also present.

The DMD gene was investigated, with multiple-PCR and MLPA excluding the presence of deletions and duplications. Sequence analysis did not demonstrate the presence of point mutations. cDNA analysis showed the existence of a band of higher molecular weight than expected (Figure 6A). Direct sequencing of RT-PCR products revealed the insertion of 53 bp (c.9563_9564ins53) between exons 65 and 66 (Figure 6B). Further analysis demonstrated that the inserted fragment corresponded to a portion of intron 65. Its insertion into natural transcript determines the creation of a premature stop codon (p.Thr3188 = fsX7), which is responsible for the complete absence of dystrophin at IHC analysis.
Figure 6

Patient XL: An intronic nucleotide substitution activates a cryptic splice site leading to pseudoexon creation. The mutation is localized in intron 65 (see schematic representation of the DMD gene). A. Sequence analysis. The electropherogram depicts the insertion of 53 bp between exons 65 and 66. This insertion creates a stop codon (TGA, red box) and results in the production of a truncated protein (p.Thr3188ThrfsX7). The insertion is determined by a nucleotide substitution (c.9564-426T>G) in IVS 65, which activates a cryptic splice site. The schematic representation of IVS65 under the electropherogram depicts the position of the intronic mutation and the sequence inserted into intron 65. B. cDNA analysis depicts a band with higher molecular weight than control (Ctr) in the patient, demonstrating the insertion of 53 bp. C. Bioinformatic analysis: 5' Splice Site score distribution in patient (mutated, green) versus control (wild type, blue). The mutation is localized in a silent splice site consensus sequence included in the intron and increases the MaxENT score, that gives the probability that a sequence is a functional splice site, from a value of 6.8 to a value of 10.4. The obtained maxENT scores, suggest that the mutation activates a cripitc 5'ss leading to inclusion of the exon in the mature transcript. The substitution involves one of the most important and conserved bases of the consensus sequence, as shown in the schematic representation on the right, which illustrates the relative frequency of different bases in the 5' splice site consensus sequence (the size of the letter indicating each nucleotide reflects its importance in the consensus sequence).

To better understand the molecular mechanism underlying this genetic rearrangement, we further investigated genomic sequence and found a nucleotide substitution at position -426 in intron 65 (c.9564-426 T>G); this mutation is located 5 bp downstream from the inserted sequence. It has not been previously described, and had a "de novo" origin since it was not present in the patient's mother.

Bio-informatic analysis (Figure 6C) showed that this mutation is localized in a silent splice site consensus sequence included in the intron. The substitution involves one of the most important and conserved bases of the sequence and markedly increases the splice site strength, changing the maxENT score from a value of 6.8 in wild type to a value of 10.4 in the patient, and making it higher than is found in normal exons (8.1). The activation of this criptic 5'splice site and its interaction with one pre-existing, but normally silent, acceptor splice site within intron 65 leads to the insertion of a 53-bp pseudoexon.

Discussion

We performed a clinical and molecular study of a sample of 47 Italian dystrophinopathic patients (41 DMD and 6 BMD) carrying nucleotide alterations in the DMD gene. All types of mutations were represented, including 10 micro-insertions or deletions, 21 nonsense substitutions, 9 splice-site mutations, and 1 missense mutation. Overall 16 of these mutations had not been previously described.

From this cohort, we presented in detail five cases paradigmatic of mechanisms that are responsible for complex rearrangements or novel exceptions to the reading frame rule. Two patients carried nonsense mutations associated to unexpected BMD phenotype, the other three represent unconventional splice-site mutations, not localized in canonical splice sites or with variable transcriptional effects. Three of these five interesting mutations are also novel.

Nonsense mutations potentially determine the interruption of dystrophin synthesis, mRNA decay, and degradation of truncated dystrophin molecules, unless they are located in the 5' or 3' gene regions [31, 32]. In particular, two mechanisms are thought to be responsible for the variable effect of nonsense mutations located in these gene regions, namely initiation of translation from downstream ATG codons (in the case of mutations located at the 5' end) and escape from nonsense-mediated decay (for substitutions in the 3' portion). In our sample, patients I and III carried a nonsense mutation located at the 3' of the gene associated with a BMD phenotype of variable severity, with partial production of dystrophin protein demonstrated by IHC and WB analysis (Figure 2). Similar results have been described in other cases. A detailed analysis of the Leiden database http://www.dmd.nl indicates that the majority of mutations located in the final 5 exons of the dystrophin gene, even if determining production of an out-of frame transcript, are associated with BMD or intermediate phenotypes; only 11 are associated with DMD. In particular, the c.10453insC mutation has been described in 5 different patients: 1 showed a DMD phenotype; 2 had a mild Becker-like muscular involvement; and 2 subjects, of African and French origin, presented with an intermediate phenotype [33-34, Leiden muscular dystrophy database].

The mutation c.10783C>T has been described once [35] in one DMD patient. We hypothesize that the mutations located at the end of DMD cDNA bypass mRNA decay as previously demonstrated [32], preserving the protein functional domains responsible for anchorage of the protein to the membrane.

While the efficiency of nonsense-mediated mRNA decay can differ among patients carrying different distal mutations, leading to different phenotypes, the mechanisms influencing this process are not known. Furthermore, this high spectrum of variability, which is also evidenced among BMD presentations, suggests the influence of other factors that remain to be investigated. The exact location of the mutation may also be considered an important factor. It is worth mentioning that in some cases nonsense mutations at the 3' end of the gene can be associated with the DMD phenotype, as well, as we observed in two patients carrying two nonsense mutations in exons 74 and 75 (p.Gln3551X; p.Asn3462LysfsX3).

Interesting insights into dystrophin mRNA maturation may be derived from patients VI, XXXV, and XL, who carry different mutations affecting the splicing process.

The mechanisms that determine alternative splicing are complex and still not completely characterized. To date, disease-causing splicing mutations described in DMD and BMD populations seems to mainly affect canonical splice site sequences; the effect of these mutations on mRNA processing has been investigated in few published cases [17].

The behaviour of mutations involving the splice site is not always completely predictable: in patient VI a leaky novel splice site mutation determines the simultaneous creation of two PCR products reflecting the presence of both a full length and a spliced transcript (Figure 4).

The efficiency of the novel splicing signal inversely correlates with disease severity and must be considered when predicting the effect of the mutation. The case of patient XXXV demonstrates how splicing can be altered not only by mutations localized in the canonical splice sites, but also by mutations in the neighbouring exonic sequences. A nucleotide substitution located near the exon-intron boundary, first interpreted as a missense mutation, was demonstrated to have a strong effect on splicing. This substitution determines the activation of a cryptic splice site, resulting in skipping of the last four nucleotides of exon 65, with a consequent reading frame shift resulting in a severe phenotype (Figure 5).

Finally, splicing can also be altered by mutations of deep intronic regions located at sites that can be recognized as splice site consensus sequences. In these cases, transcript analysis associated with bioinformatic predictions may allow the clarification of molecular mechanisms underlying the disease phenotype. So far, the creation of additional splice sites in the central part of an intron has been reported in few cases [13, 36]. In patient XL, a single nucleotide substitution in a consensus sequence that is normally silent increases its efficiency and determines the insertion of a pseudo-exon (Figure 6).

Conclusion

All these cases underscore the importance of a complete study of the gene, including exon-intron boundary sequencing and transcript analysis, which has been demonstrated to be the only definitive analysis. Nonetheless, muscle biopsy remains highly informative because dystrophin mRNA is hardly extracted from blood samples and dystrophin protein can be analyzed in muscle tissue.

Also, when a complete molecular characterization is achieved, the interpretation of genetic data "per se" might be challenging. The reading frame rule can be used to predict the effect of the majority of mutations, but some exceptions have been described, especially among nucleotide alterations. Occasionally, these exceptions may provide support for another general rule, as it occurs with the stop codon point mutations located in the 5' part of the DMD gene whereby the initiation of translation occurs from downstream AUG codons and results in BMD phenotypes [30]. However such a general rule can be hardly recognized for patients carrying nonsense mutations located at 3' part of the gene, that may lead to DMD, intermediate or BMD phenotypes without an apparent rationale. In other instances, such as the splicing variants described in patient VI and XXXV, the molecular data evaluation should incorporate both mRNA data and bioinformatic predictions in order to draw a reliable conclusion on expected phenotype.

These instances support the notion that only a thorough investigation of clinical features, muscle biopsy data and molecular findings would finally give to the molecular data interpretation a prognostic value in all dystrophinopatic patients.

Declarations

Acknowledgements and Funding

We wish to thank the patients and their families for their support and collaboration. This research received funding support from Telethon - UILDM Grant GUP07009 (GPC). Telethon Genetic Biobanks Network GTB07001E was the source of the DNA used in this study. Eurobiobank project QLTR-2001-02769 is also gratefully acknowledged.

Authors’ Affiliations

(1)
Dino Ferrari Centre, Department of Neurological Sciences, University of Milan, I.R.C.C.S. Foundation Cà Granda, Ospedale Maggiore Policlinico
(2)
Scientific Institute IRCCS E. Medea
(3)
Laboratory of Medical Genetics, I.R.C.C.S. Foundation Cà Granda, Ospedale Maggiore Policlinico

References

  1. Davies KE, Smith TJ, Bundey S, et al: Mild and severe muscular dystrophy associated with deletions in Xp21 of the human × chromosome. J Med Genet. 1988, 25: 9-13. 10.1136/jmg.25.1.9.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Emery AE: Population frequencies of inherited neuromuscular diseases--a world survey. Neuromuscul Disord. 1991, 1: 19-29. 10.1016/0960-8966(91)90039-U.View ArticlePubMedGoogle Scholar
  3. Emery AE: Some unanswered questions in Duchenne muscular dystrophy. Neuromuscul Disord. 1994, 4 (4): 301-3. 10.1016/0960-8966(94)90065-5.View ArticlePubMedGoogle Scholar
  4. Beggs AH, Hoffman EP, Snyder JR, et al: Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet. 1991, 49 (1): 54-67.PubMedPubMed CentralGoogle Scholar
  5. Curtis , Haggerty : Deletion and duplication analysis in males affected with Duchenne or Becker muscular dystrophy. Methods in molecular medicine. Edited by: Anderson LVB. 2001, Totowa NJ: Humana Press, 43: 53-84.Google Scholar
  6. Flanigan KM, von Niederhausern A, Dunn DM, et al: Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet. 2003, 72 (4): 931-9. 10.1086/374176.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Sedlácková J, Vondrácek P, Hermanová M, et al: Point mutations in Czech DMD/BMD patients and their phenotypic outcome. Neuromuscul Disord. 2009, 11: 749-53.View ArticleGoogle Scholar
  8. Tuffery-Giraud S, Béroud C, Leturcq F, et al: Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat. 2009, 30: 934-45. 10.1002/humu.20976.View ArticlePubMedGoogle Scholar
  9. Roberts RG, Gardner RJ, Bobrow M: Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations. Hum Mutat. 1994, 4: 1-11. 10.1002/humu.1380040102.View ArticlePubMedGoogle Scholar
  10. Flanigan KM, Dunn DM, von Niederhausern A, et al: Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat. 2009, 30: 1657-66. 10.1002/humu.21114.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Flanigan KM, Dunn DM, von Niederhausern A, et al: Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. Hum Mutat. 2011, 32 (3): 299-308. 10.1002/humu.21426.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Sironi M, Corti S, Locatelli F, Cagliani R, Comi GP: A novel splice site mutation (3157+1G>T) in the dystrophin gene causing total exon skipping and DMD phenotype. Hum Mutat. 2001, 17 (3): 239-10.1002/humu.18. Erratum in: Hum Mutat 2001, 18(6): 552View ArticlePubMedGoogle Scholar
  13. Gurvich OL, Tuohy TM, Howard MT, et al: DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy. Ann Neurol. 2008, 63: 81-9. 10.1002/ana.21290.View ArticlePubMedGoogle Scholar
  14. Béroud C, Carrié A, Beldjord C, et al: Dystrophinopathy caused by mid-intronic substitutions activating cryptic exons in the DMD gene. Neuromuscul Disord. 2004, 14: 10-8.View ArticlePubMedGoogle Scholar
  15. Tuffery-Giraud S, Chambert S, Demaille J, Claustres M: Point mutations in the dystrophin gene: evidence for frequent use of cryptic splice sites as a result of splicing defects. Hum Mutat. 1999, 14: 359-68. 10.1002/(SICI)1098-1004(199911)14:5<359::AID-HUMU1>3.0.CO;2-K.View ArticlePubMedGoogle Scholar
  16. Tran VK, Zhang Z, Yagi M, Nishiyama A, Habara Y, Takeshima Y, Matsuo M: A novel cryptic exon identified in the 3' region of intron 2 of the human dystrophin gene. J Hum Genet. 2005, 50: 425-33. 10.1007/s10038-005-0272-6.View ArticlePubMedGoogle Scholar
  17. Tuffery-Giraud S, Saquet C, Chambert S, Claustres M: Pseudoexon activation in the DMD gene as a novel mechanism for Becker muscular dystrophy. Hum Mutat. 2003, 21: 608-14. 10.1002/humu.10214.View ArticlePubMedGoogle Scholar
  18. Welch EM, Barton ER, Zhuo J, et al: PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007, 447: 87-91. 10.1038/nature05756.View ArticlePubMedGoogle Scholar
  19. Hamed SA: Drug evaluation: PTC-124--a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs. 2006, 9 (11): 783-9.PubMedGoogle Scholar
  20. Klein CJ, Coovert DD, Bulman DE, Ray PN, Mendell JR, Burghes AH, et al: Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet. 1992, 50: 950-9.PubMedPubMed CentralGoogle Scholar
  21. Nicholson LV, Davison K, Johnson MA, et al: Dystrophin in skeletal muscle. II. Immunoreactivity in patients with Xp21 muscular dystrophy. J Neurol Sci. 1989, 94 (1-3): 137-146. 10.1016/0022-510X(89)90224-4.View ArticlePubMedGoogle Scholar
  22. Prelle A, Comi GP, Tancredi L, et al: Sarcoglycan deficiency in a large Italian population of myopathic patients. Acta Neuropathol. 1998, 96: 509-514. 10.1007/s004010050926.View ArticlePubMedGoogle Scholar
  23. Minetti C, Sotgia F, Bruno C, et al: Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet. 1998, 18: 365-368. 10.1038/ng0498-365.View ArticlePubMedGoogle Scholar
  24. Valle G, Faulkner G, De Antoni A, et al: Telethonin, a novel sarcomeric protein of heart and skeletal muscle. FEBS Lett. 1997, 415: 163-168. 10.1016/S0014-5793(97)01108-3.View ArticlePubMedGoogle Scholar
  25. Schouten JP, McElgunn CJ, Waaijer R, et al: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002, 30 (12): e57-10.1093/nar/gnf056.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Roberts RG, Barby TF, Manners E, Bobrow M, Bentley DR: Direct detection of dystrophin gene rearrangements by analysis of dystrophin mRNA in peripheral blood lymphocytes. Am J Hum Genet. 1991, 49: 298-310.PubMedPubMed CentralGoogle Scholar
  27. Den Dunnen JT, Antonarakis SE: Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat. 2000, 15: 7-12. 10.1002/(SICI)1098-1004(200001)15:1<7::AID-HUMU4>3.0.CO;2-N. Erratum in: Hum Mutat 2002, 20: 403View ArticlePubMedGoogle Scholar
  28. Yeo G, Burge CB: Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol. 2004, 11: 377-94. 10.1089/1066527041410418.View ArticlePubMedGoogle Scholar
  29. Eng L, Coutinho G, Nahas S, et al: Nonclassical splicing mutations in the coding and noncoding regions of the ATM Gene: maximum entropy estimates of splice junction strengths. Hum Mutat. 2004, 23: 67-76. 10.1002/humu.10295.View ArticlePubMedGoogle Scholar
  30. Flanigan KM, Dunn DM, von Niederhausern A, et al: DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy. Neuromuscul Disord. 2009, 19 (11): 743-8. 10.1016/j.nmd.2009.08.010.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Gurvich OL, Maiti B, Weiss RB, Aggarwal G, Howard MT, Flanigan KM: DMD exon 1 truncating point mutations: amelioration of phenotype by alternative translation initiation in exon 6. Hum Mutat. 2009, 30 (4): 633-40. 10.1002/humu.20913.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Kerr TP, Sewry CA, Robb SA, Roberts RG: Long mutant dystrophins and variable phenotypes: evasion of nonsense-mediated decay?. Hum Genet. 2001, 109 (4): 402-7. 10.1007/s004390100598.View ArticlePubMedGoogle Scholar
  33. Deburgrave N, Daoud F, Llense S, et al: Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum Mutat. 2007, 28: 183-95. 10.1002/humu.20422.View ArticlePubMedGoogle Scholar
  34. Daoud F, Angeard N, Demerre B, et al: Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. Hum Mol Genet. 2009, 18 (20): 3779-94. 10.1093/hmg/ddp320.View ArticlePubMedGoogle Scholar
  35. Spitali P, Rimessi P, Fabris M, et al: Exon skipping-mediated dystrophin reading frame restoration for small mutations. Hum Mutat. 2009, 30 (11): 1527-34. 10.1002/humu.21092.View ArticlePubMedGoogle Scholar
  36. Comi GP, Ciafaloni E, de Silva HA, et al: A G+1-->A transversion at the 5' splice site of intron 69 of the dystrophin gene causing the absence of peripheral nerve Dp116 and severe clinical involvement in a DMD patient. Hum Mol Genet. 1995, 4 (11): 2171-4. 10.1093/hmg/4.11.2171. Erratum in: Hum Mol Genet 1996, 5(4): 562View ArticlePubMedGoogle Scholar
  37. Saad FA, Mostacciuolo ML, Trevisan CP, et al: Novel mutations and polymorphisms in the human dystrophin gene detected by double-strand conformation analysis. Hum Mutat. 1997, 9 (2): 188-90. 10.1002/(SICI)1098-1004(1997)9:2<188::AID-HUMU15>3.0.CO;2-Z.View ArticlePubMedGoogle Scholar
  38. Mendell JR, Buzin CH, Feng J, et al: Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. Neurology. 2001, 57 (4): 645-50.View ArticlePubMedGoogle Scholar
  39. Taylor PJ, Maroulis S, Mullan GL, et al: Measurement of the clinical utility of a combined mutation detection protocol in carriers of Duchenne and Becker muscular dystrophy. J Med Genet. 2007, 44 (6): 368-72. 10.1136/jmg.2006.047464.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Tuffery-Giraud S, Saquet C, Chambert S, et al: The role of muscle biopsy in analysis of the dystrophin gene in Duchenne muscular dystrophy: experience of a national referral centre. Neuromuscul Disord. 2004, 14 (10): 650-8. 10.1016/j.nmd.2004.05.002.View ArticlePubMedGoogle Scholar
  41. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/12/37/prepub

Copyright

© Magri et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement